FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle
E S
ES
Department of Surgery, Washington University Medical Center, St Louis, Missouri.
Perdrizet
G A
GA
So
S
S
Jendrisak
M D
MD
White
H M
HM
Marsh
J W
JW
D058186:Acute Kidney Injury / Q000628:therapy; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000410:Alanine Transaminase / Q000097:blood; D001379:Azathioprine / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000503:physiopathology*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D016559:Tacrolimus / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous
D000305:Adrenal Cortex Hormones; D016853:Muromonab-CD3; D016572:Cyclosporine; D000410:Alanine Transaminase; D001379:Azathioprine; D001663:Bilirubin; D011241:Prednisone; D016559:Tacrolimus